TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chinese participants must have Chinese parents and grandparents, all of whom were born in China.~* Healthy status as defined by absence of evidence of any active or chronic disease~* Participants whose body weight is ≥50 to \<80 kg and body mass index is ≥18.5 to \<26 kg/m2~Exclusion Criteria:~* Participants with a history of stomach, vagus nerve, or intestinal surgery (except for appendectomy)~* Participants who have a history of allergic symptoms including food allergy (Note: Non-active allergic rhinitis will be allowed)~* Participants who require chronic drug therapy or those who have used drugs within 3 days prior to screening or within 14 days prior to Day -1~* Participants who have used alcohol-containing, caffeine-containing, grapefruit containing, or St. John's wort-containing products within 72 hours prior to Day -1~* Participants who have used tobacco- or nicotine-containing products within 24 weeks prior to screening~* Participants who have donated \> 400 mL of blood within 12 weeks or \> 200 mL of blood within 4 weeks prior to screening, or have donated any amount of blood between screening and Day -1

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Baloxavir Marboxil 40 mg (Type: EXPERIMENTAL): None
- Baloxavir Marboxil 80 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic non-small cell lung cancer (i.e. cancer that has spread from where it started) which is EGFR mutation positive~* Caucasian female or male patients aged 18 years or over~* Measurable disease, i.e. at least one lesion, not previously irradiated, as ≥ 10 mm in the longest diameter (≥ 15 mm in short axis for lymph node )~Exclusion Criteria:~* Prior adjuvant chemotherapy or other systemic anti-cancer treatment less than 6 month, or palliative radiotherapy less than 4 weeks prior to start of study treatment.~* Brain metastases or spinal cord compression, unless treated and stable without steroids~* Any clinically significant illness, which will jeopardize the patients' safety and their participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): gefitinib 250mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lilly's Emotional and Physical Symptoms of Depression Study (LEAPS)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Meet criteria for major depressive disorder according to the DSM-IV diagnostic criteria~* Outpatients at least 18 years of age~* Sign the informed consent~* All females must test negative for a urine pregnancy test at visit 1. Females of child bearing potential must agree to utilize medically acceptable and reliable means of birth control~* Have a level of understanding sufficient to communicate with the investigator and are able to complete all patient self-rated scales in the study~Exclusion Criteria:~* Are investigator site personnel directly affiliated with the study or immediate family~* Are employed by Eli Lilly and Company~* Have received treatment within the last 30 days or are currently enrolled in a study with a drug that has not received regulatory approval for any indication at time of study entry~* Current substance dependence, excluding nicotine and caffeine~* Treatment with a monoamine oxidase inhibitor within 14 days prior to visit 1 or potential need to use an MAOI within 5 days after discontinuation of study drug~* Acute liver injury or severe (Child-Pugh Class C) cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Inhalational Anaesthetics in Cognitive Functions in Down Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) classification I, II or III~* Down syndrome patients~* must be able to undergone general anaesthesia~* dental surgery necessity~Exclusion Criteria:~* severe dementia~* severe hearing, vision, speaking problems

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sevoflurane group (Type: ACTIVE_COMPARATOR): inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
- Desflurane group (Type: ACTIVE_COMPARATOR): inhalation anaesthetic Desflurane, 1 M.A.C. during surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least 12 years of age~* Diagnosis of asthma~* Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol~Exclusion Criteria:~* Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers~* Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): budesonide
- 3 (Type: ACTIVE_COMPARATOR): formoterol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who have \>/= 80 mL blood loss during their menstrual cycles and desire contraception~Exclusion Criteria:~* Post menopausal menstrual cycle \< 21 days or \> 35 days~* Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours (Type: EXPERIMENTAL): Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
- Medroxyprogesterone acetate (MPA) (Type: ACTIVE_COMPARATOR): Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Three Medications to Treat Diarrhea in Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age~* Acute diarrhea illness with symptoms onset within 48 hours of study entry~* Minimum of 3 unformed stools in 24 hours before study entry~* Most recent stool is unformed~* Abdominal discomfort/wind (intensity mild to severe) within 4 hours of study entry~* Women of childbearing potential must have a negative pregnancy test at screening~* Willing to adhere to the prohibitions and restrictions specified in this protocol~* Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study~Exclusion Criteria:~* Requiring hospital admission, parenteral hydration or antibiotic therapy Axillary temperature \>38.2°C or oral temperature \>38.6°C~* History or clinical evidence of gross blood or pus in stool in current illness~* Signs or symptoms of orthostatic hypotension~* Unable to take medication and fluids by mouth~* History of chronic gastrointestinal disease, hepatic or renal insufficiency, or other significant medical condition that could be aggravated by untreated acute diarrhea~* Immunodeficiency (e.g. those with acquired immunodeficiency syndrome \[AIDS\] or known human immunodeficiency virus \[HIV\] infection, or undergoing chemotherapy or radiotherapy)~* Intake of antibiotics, oral antifungals, quinidine or ritonavir within 7 days, antidiarrhoeal, promotility drugs (e.g., metoclopramide, domperidone), antiflatulents (e.g., simeticone, activated charcoal) or probiotics or bismuth salts within 48 hours, or any analgesic within 6 hours prior to study entry Hypersensitivity to loperamide, yeast, or any component of study formulations~* Pregnant or breast-feeding~* Unable to comply with the protocol requirements and schedule~* Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study~* Use of opiates (as 'recreational' drugs and as painkillers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loperamide/simeticone Caplets (Type: EXPERIMENTAL): Drug (including placebo)
- Loperamide/simeticone Chewable Tablets (Type: ACTIVE_COMPARATOR): Drug (including placebo)
- Probiotic Capsules (Type: ACTIVE_COMPARATOR): Drug (including placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Stress Urinary Incontinence Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are greater than 20 years of age.~* Are female outpatients.~* Present with SUI based on the disease diagnostic criteria, average at least one incontinent episode per day on the screening diary, and have had symptoms of SUI for a minimum of 3 months prior to study entry.~* Are women of non-childbearing potential by reason of hysterectomy, other surgery, or natural menopause, or are women of childbearing potential who test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a medically accepted means of contraception (for example, intrauterine device \[IUD\], oral or injectable contraceptives, implant, barrier device, sterilization, abstinence, or sex with a vasectomized male partner) for the duration of the study. Women using oral contraceptives or hormone replacement therapy must have a stable dose and regimen for greater than or equal to 3 months prior to entry into the study.~* Have no language barrier, agree to comply with the requirements of the protocol, and sign a written informed consent document prior to entry into the study.~Exclusion Criteria:~* Suffer from severe constipation (for example, have impacted rectum at time of physical examination despite recent evacuation).~* Has a physical examination, neurological and/or vaginal examination results which, in the opinion of the investigator, should exclude the subject.~* Are on a medication regimen (including diuretics) for which dose and/or frequency has not been stable for at least 12 weeks prior to randomization, or is anticipated to change during the course of the study.~* Have had any major inpatient surgery within 3 months prior to study entry.~* Have current diagnosis of any of the following conditions, disorders, or diseases of the genito-urinary tract: Ureteric, bladder, urethral, or rectal fistula~* Uncorrected congenital abnormality leading to urinary incontinence~* Detrusor instability or noncompliant bladder~* Adult enuresis~* Voiding difficulty (i.e., subject complains of difficulty emptying their bladder).

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of diabetes mellitus~* Understanding of study and provision of written informed consent~* 18 years of age or older~* No history of any other retinal vascular disease, glaucoma, or other disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed)~* Other than cataract surgery, no history of intraocular surgery, ocular laser treatments for any retinal disease, or ocular injections for diabetic macular edema or proliferative disease No media opacity precluding good retinal photography~Exclusion Criteria:~* No diagnosis of diabetes mellitus~* Potential subject cannot understand study or informed consent~* A history of retinal vascular disease other than diabetic retinopathy that may affect the appearance of the retina or optic disc~* Previous intraocular surgery including cataract; previous laser to the retina; or previous intraocular injections for the treatment of diabetic retinopathy~* Pregnant women or women with gestational diabetes mellitus~* A media opacity in either eye that is severe enough to preclude good retinal photography~* Permanent vision impairment in one or both eyes~* The participant is contraindicated for imaging with fundus imaging systems used in the study:~* Participant is hypersensitive to light~* Participant recently received photodynamic therapy (PDT)~* Participant uses drugs that cause photosensitivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consenting patients were eligible for enrollment if they:~  1. were 18-65 years of age,~ 2. had endoscopically diagnosed active duodenal ulcers within the previous 72 hours and~ 3. the number of ulcers was at least one, but no more than two with the larger diameter 0.3-2.0cm.~Exclusion Criteria:~* Patients were ineligible if they:~  1. had cancerous or complex ulcers, Zollinger-Ellison syndrome, esophageal erosion or ulcer, varices of esophagus or fundus of stomach, or pyloric stenosis,~ 2. had a known history of gastric acid suppression operation, esophageal operation or peptic operation other than simple closure of perforation,~ 3. had severe complications (e.g., pyloric obstruction, active bleeding under endoscope), severe other diseases of digestive tract such as Crohn's disease and ulcerative colitis, and severe other systemic diseases,~ 4. were female patients who were breast feeding, pregnant, or intended to become pregnant during the study,~ 5. had taken proton pump inhibitors within the 5 days or for more than three consecutive days within the two weeks immediately preceding start of study drug,~ 6. participated in a clinical trial with an investigational drug or device within the past three months,~ 7. had hypersensitivity or idiosyncratic reaction to omeprazole or any other benzimidazole,~ 8. had alcoholic intemperance, drug addiction or any other improper habits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg ilaprazole (Type: EXPERIMENTAL): None
- 20 mg omeprazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 5-day repeated administrations and the follow-up observation in the preceding study (156-04-001)~* Patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (156-04-001)~Exclusion Criteria:~* Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination~* Patients with any of the following complications~  * Uncontrolled hypertension~ * Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)~* Patients with any of the following complications or history thereof~  * Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)~ * Inability to personally give consent due to a mental disease ~* Patients with SBP (in sitting position) \<90 mm Hg (at screening examination)~* Patients with history of massive bleeding or bleeding tendency~* Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination~* Pregnant women, lactating women, or women who may become or plan to become pregnant~* Patients who received any investigational drug other than OPC-41061 within 30 days prior to commencement of administration of OPC-41061~* Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Replacement Therapy in Pinealectomized Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with pinealectomy and all of the following criteria were considered for admission to the clinical trial:~* children, adolescents and young adults 0 months to 25 years of age;~* signed written informed consent (patient or his/her parents/legal guardian);~* willing and able to complete the clinical trial procedures, as described in the protocol~* no recurring tumor after pinealectomy and subsequent chemotherapy~* absence of circulating melatonin evaluated by salivary melatonin Elisa assay~Exclusion Criteria:~* patients with cardiac arrhythmias~* potentially non-compliant subjects judged by the investigator to be unsuitable for the study

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melatonin Replacement Therapy (Type: EXPERIMENTAL): Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete